SeaCrest Wealth Management LLC Has $1.66 Million Stake in Pfizer Inc. $PFE

SeaCrest Wealth Management LLC reduced its position in Pfizer Inc. (NYSE:PFE) by 25.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 64,428 shares of the biopharmaceutical company’s stock after selling 22,128 shares during the quarter. SeaCrest Wealth Management LLC’s holdings in Pfizer were worth $1,655,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently made changes to their positions in PFE. Peak Asset Management LLC grew its stake in Pfizer by 1.4% during the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock worth $697,000 after purchasing an additional 402 shares during the period. Community Bank & Trust Waco Texas boosted its holdings in shares of Pfizer by 0.6% during the 3rd quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock worth $1,703,000 after buying an additional 412 shares in the last quarter. CVA Family Office LLC increased its stake in shares of Pfizer by 3.3% in the 3rd quarter. CVA Family Office LLC now owns 12,915 shares of the biopharmaceutical company’s stock valued at $329,000 after acquiring an additional 413 shares in the last quarter. Boltwood Capital Management boosted its stake in Pfizer by 0.7% during the third quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company’s stock worth $1,485,000 after acquiring an additional 420 shares in the last quarter. Finally, Beverly Hills Private Wealth LLC grew its holdings in Pfizer by 1.5% in the third quarter. Beverly Hills Private Wealth LLC now owns 27,955 shares of the biopharmaceutical company’s stock worth $712,000 after purchasing an additional 421 shares during the period. 68.36% of the stock is owned by institutional investors.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approved Pfizer’s GLP‑1 weight‑management drug Xianweiying, opening a large market and adding a growth avenue beyond COVID products. Pfizer’s Weight Management Drug Wins China Approval
• Positive Sentiment: Early Phase‑2 data for trispecific antibody tilrekimig showed meaningful eczema improvement with a favorable safety profile — a successful later‑stage outcome could materially expand Pfizer’s immunology franchise. How Tilrekimig’s Trispecific Eczema Data At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer launched a new early‑stage oncology trial for PF‑07994525, extending its cancer pipeline and showing continued R&D investment that could produce longer‑term revenue drivers. Pfizer Advances Early‑Stage Cancer Candidate PF‑07994525
• Positive Sentiment: Completed Phase‑2 toddler study for Pfizer’s next‑gen pneumococcal vaccine advances that program toward later‑stage trials and potential label expansion. Pfizer Advances Next‑Gen Pneumococcal Vaccine
• Positive Sentiment: Scotiabank reiterated a Buy rating on Pfizer, which may support investor confidence and act as a near‑term positive catalyst for the stock. Scotiabank Sticks to Their Buy Rating for Pfizer (PFE)
• Neutral Sentiment: Analyst/outlet coverage highlights Pfizer’s high dividend yield (~6.5%) and deep discount from prior highs, framing the stock as an income/value play for long‑term investors. 1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever
• Neutral Sentiment: Industry coverage and commentary (health‑care roundups) mention Pfizer alongside peers — useful context but not an immediate stock mover. Health Care Roundup: Market Talk
• Neutral Sentiment: Pfizer commentary on navigating regulatory uncertainty (company expert piece) underlines the firm’s focus on compliance but has limited immediate market impact. Be nimble, be ready: how to tackle regulatory uncertainty in clinical trials
• Negative Sentiment: Market reports show Pfizer’s share price dipped more than the broader market in recent sessions, reflecting short‑term selling pressure and investor caution. Pfizer (PFE) Sees a More Significant Dip Than Broader Market
• Negative Sentiment: Duplicate market‑movement coverage highlights the intraday weakness and may reinforce momentum selling. Pfizer (PFE) Sees a More Significant Dip Than Broader Market: Some Facts to Know
• Negative Sentiment: Competitive pressure: Bristol Myers’ deep late‑stage pipeline coverage reminds investors that peer advancements could divert future market share and investor attention away from Pfizer’s franchises. Is Bristol Myers’ Deep Pipeline the Key to Future Growth?

Pfizer Stock Up 0.1%

Pfizer stock traded up $0.04 during midday trading on Friday, hitting $26.90. 3,442,513 shares of the stock were exchanged, compared to its average volume of 46,104,438. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.94. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The business’s 50-day moving average price is $26.47 and its 200-day moving average price is $25.51. The stock has a market capitalization of $152.95 billion, a price-to-earnings ratio of 19.78 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. During the same quarter last year, the firm earned $0.63 EPS. The company’s quarterly revenue was down 1.2% compared to the same quarter last year. On average, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on PFE shares. Citigroup started coverage on shares of Pfizer in a report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price objective on the stock. HSBC reissued a “buy” rating and issued a $29.00 price objective on shares of Pfizer in a research note on Wednesday, December 10th. Royal Bank Of Canada started coverage on Pfizer in a research report on Tuesday, February 24th. They set an “underperform” rating and a $25.00 target price on the stock. Wolfe Research set a $24.00 target price on Pfizer and gave the stock an “underperform” rating in a report on Wednesday, December 17th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $28.05.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.